468 related articles for article (PubMed ID: 16407588)
21. Mechanisms of disease progression in nonalcoholic fatty liver disease.
Jou J; Choi SS; Diehl AM
Semin Liver Dis; 2008 Nov; 28(4):370-9. PubMed ID: 18956293
[TBL] [Abstract][Full Text] [Related]
22. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis.
Wieckowska A; Papouchado BG; Li Z; Lopez R; Zein NN; Feldstein AE
Am J Gastroenterol; 2008 Jun; 103(6):1372-9. PubMed ID: 18510618
[TBL] [Abstract][Full Text] [Related]
23. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
[TBL] [Abstract][Full Text] [Related]
24. Microsomal triglyceride transfer protein and nonalcoholic fatty liver disease.
Pereira IV; Stefano JT; Oliveira CP
Expert Rev Gastroenterol Hepatol; 2011 Apr; 5(2):245-51. PubMed ID: 21476919
[TBL] [Abstract][Full Text] [Related]
25. The potential role of genes in nonalcoholic fatty liver disease.
Day CP
Clin Liver Dis; 2004 Aug; 8(3):673-91, xi. PubMed ID: 15331069
[TBL] [Abstract][Full Text] [Related]
26. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites.
Neuschwander-Tetri BA
Hepatology; 2010 Aug; 52(2):774-88. PubMed ID: 20683968
[TBL] [Abstract][Full Text] [Related]
27. Hepatic lipid metabolism and non-alcoholic fatty liver disease.
Tessari P; Coracina A; Cosma A; Tiengo A
Nutr Metab Cardiovasc Dis; 2009 May; 19(4):291-302. PubMed ID: 19359149
[TBL] [Abstract][Full Text] [Related]
28. Environmental and genetic determinants of fatty liver in humans.
Kantartzis K; Schick F; Häring HU; Stefan N
Dig Dis; 2010; 28(1):169-78. PubMed ID: 20460907
[TBL] [Abstract][Full Text] [Related]
29. MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes.
Larter CZ; Yeh MM; Williams J; Bell-Anderson KS; Farrell GC
J Hepatol; 2008 Sep; 49(3):407-16. PubMed ID: 18534710
[TBL] [Abstract][Full Text] [Related]
30. [Fatty acid composition of liver lipids in chronic hepatitis, liver cirrhosis and fatty liver].
Mokhov VM; Bliuzdin IuA
Vopr Med Khim; 1987; 33(3):38-42. PubMed ID: 3630012
[TBL] [Abstract][Full Text] [Related]
31. Interaction of metabolic syndrome, nonalcoholic fatty liver disease and chronic hepatitis C.
Rafiq N; Younossi ZM
Expert Rev Gastroenterol Hepatol; 2008 Apr; 2(2):207-15. PubMed ID: 19072356
[TBL] [Abstract][Full Text] [Related]
32. [Chromatographic study of liver lipids and fatty acids in alcoholic hepatic steatosis].
Bertrand JL; Mallein R; Sabater P; Brette R
Biol Gastroenterol (Paris); 1971; 3():Suppl 3:219-24. PubMed ID: 5126101
[No Abstract] [Full Text] [Related]
33. The significance of differences in fatty acid metabolism between obese and non-obese patients with non-alcoholic fatty liver disease.
Nakamuta M; Kohjima M; Higuchi N; Kato M; Kotoh K; Yoshimoto T; Yada M; Yada R; Takemoto R; Fukuizumi K; Harada N; Taketomi A; Maehara Y; Nakashima M; Enjoji M
Int J Mol Med; 2008 Nov; 22(5):663-7. PubMed ID: 18949388
[TBL] [Abstract][Full Text] [Related]
34. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis.
Marra F; Gastaldelli A; Svegliati Baroni G; Tell G; Tiribelli C
Trends Mol Med; 2008 Feb; 14(2):72-81. PubMed ID: 18218340
[TBL] [Abstract][Full Text] [Related]
35. Adiponectin inhibits steatotic CD95/Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C.
Wedemeyer I; Bechmann LP; Odenthal M; Jochum C; Marquitan G; Drebber U; Gerken G; Gieseler RK; Dienes HP; Canbay A
J Hepatol; 2009 Jan; 50(1):140-9. PubMed ID: 19019483
[TBL] [Abstract][Full Text] [Related]
36. Melatonin ameliorates nonalcoholic fatty liver induced by high-fat diet in rats.
Pan M; Song YL; Xu JM; Gan HZ
J Pineal Res; 2006 Aug; 41(1):79-84. PubMed ID: 16842545
[TBL] [Abstract][Full Text] [Related]
37. Nonalcoholic fatty liver disease: emerging mechanisms and consequences.
Turkish AR
Curr Opin Clin Nutr Metab Care; 2008 Mar; 11(2):128-33. PubMed ID: 18301087
[TBL] [Abstract][Full Text] [Related]
38. Recent advances in nonalcholic fatty liver disease.
Greenfield V; Cheung O; Sanyal AJ
Curr Opin Gastroenterol; 2008 May; 24(3):320-7. PubMed ID: 18408460
[TBL] [Abstract][Full Text] [Related]
39. Thioacetamide-induced hepatic damage in a rat nutritional model of steatohepatitis.
Avni Y; Shirin H; Aeed H; Matas Z; Shahmurov M; Birkenfeld S; Bruck R
J Med; 2003; 34(1-6):121-37. PubMed ID: 17682318
[TBL] [Abstract][Full Text] [Related]
40. PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.
Seo YS; Kim JH; Jo NY; Choi KM; Baik SH; Park JJ; Kim JS; Byun KS; Bak YT; Lee CH; Kim A; Yeon JE
J Gastroenterol Hepatol; 2008 Jan; 23(1):102-9. PubMed ID: 18171348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
